World / Science & Health Nov 19, 2020
Pfizer-BioNTech coronavirus vaccine deliveries could start 'before Christmas'
Final trial results showed the vaccine had a 95% success rate and no serious side effects, the drugmakers said.
Pfizer-BioNTech coronavirus vaccine deliveries could start 'before Christmas'
Final trial results showed the vaccine had a 95% success rate and no serious side effects, the drugmakers said.
China takes risk in rushing to use unproven coronavirus vaccines
China has made its unproven candidates widely available to demonstrate their safety and effectiveness to a country that has long been skeptical of vaccines.
Sinovac's COVID-19 vaccine induces quick immune response, study finds
Sinovac Biotech's experimental COVID-19 vaccine CoronaVac triggered a quick immune response but the level of antibodies produced was lower than in people who had recovered from the disease, preliminary trial results showed on Wednesday. While the early to mid-stage trials were not designed to assess ...
Pfizer reaches safety milestone for COVID-19 vaccine, CEO says
Pfizer Inc. Chief Executive Officer Albert Bourla said that a key safety milestone had been reached in the study of its COVID-19 vaccine, and the drugmaker is now preparing to seek an emergency-use authorization from U.S. regulators. Speaking at a virtual conference hosted by The ...
How Pfizer and BioNTech sprinted ahead in extraordinary race for a COVID-19 vaccine
Researchers were asked to tackle something that had never been done before: design a vaccine to stop a pandemic in its tracks in less than a year.
Moderna’s COVID-19 vaccine: What you need to know
Coming a week after similar news from Pfizer and BioNTech, Moderna's announcement offered more hope that there’s going to be a way out of the pandemic.
WHO warns against COVID-19 complacency after Moderna vaccine news
"Right now we are extremely concerned by the surge in cases we are seeing in some countries," WHO director-general Tedros Adhanom Ghebreyesus told a news briefing.
How the Moderna and Pfizer coronavirus vaccines stack up
The encouraging late-stage trial results from Pfizer Inc. and Moderna Inc. set a high bar for rivals that are expected to follow soon with their own pivotal reports.
Drugmaker Moderna says COVID-19 vaccine shows nearly 95% protection
A key advantage of Moderna's vaccine is that it does not need ultracold storage like Pfizer's, making it easier to distribute.
China under pressure to reveal vaccine data after Pfizer success
While Beijing has hailed the progress on its own own COVID-19 vaccines, it has so far yet to back this up with evidence.
Moderna COVID-19 vaccine trial reaches key goal to gauge merit
The bet among top experts in the field is that Moderna’s therapy will likely prove to be highly effective.
Experts welcomed the news but warned that the results were only based on a small number of trial volunteers who had contracted COVID-19.